We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Arcturus (ARCT) This Earnings Season?
Read MoreHide Full Article
Investors will likely focus on the progress of Arcturus Therapeutics Holdings Inc.’s (ARCT - Free Report) COVID-19 vaccine candidate on the fourth-quarter earnings call.
Arcturus’ earnings performance has been dismal over the trailing four quarters. The company’s earnings missed estimates in each of the last four quarters with the average negative surprise being 47.84%.
Shares of Arcturus have soared 399.1% so far this year against the industry‘s decrease of 14.9%.
In the last reported quarter, Arcturus delivered a negative earnings surprise of 95.74%.
Factors to Note
Arcturus has two clinical-stage candidates in its pipeline — a single dose, mRNA-based COVID-19 vaccine and a therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.
The company’s COVID-19 vaccine candidate, ARCT-021, has shown favorable immunogenicity and safety profile when the company announced interim data from a phase I/II study in November last year. Based on this study data, the FDA and Singapore Health Sciences Authority granted permission to initiate a phase II study on the candidate.
The new phase II study will continue to evaluate both single-dose and prime-boost regimens of the candidate. Potential positive data from this study will support a phase III study, planned to begin in the second quarter. The company may provide an update on the progress of the phase II study on its fourth-quarter earnings call.
The company is developing OTC therapeutic candidate, ARCT-810, in two early-stage studies. Investors may ask questions on the future path for the candidate’s development on the earnings call.
During the quarter, the company planned to progress a new pipeline candidate, ARCT-032, to clinical-stage development for treating cystic fibrosis. Ongoing clinical studies and preparation for new clinical studies are likely to have driven operating expenses during the fourth quarter. However, the company may have recorded grant revenues, which are likely to have partially offset the increase in operating expense.
Meanwhile, the company records revenues from its strategic alliances and collaborations. However, revenues from these sources vary every quarter.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Arcturus this earnings season. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Arcturus has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 92 cents per share.You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Arcturus carries a Zacks Rank #4 (Sell).
Arcturus Therapeutics Holdings Inc. Price and Consensus
Here are some biotech stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Clearside Biomedical, Inc. (CLSD - Free Report) has an Earnings ESP of +4.35% and a Zacks Rank #2.
Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) has an Earnings ESP of +3.57% and a Zacks Rank #2.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
What's in the Cards for Arcturus (ARCT) This Earnings Season?
Investors will likely focus on the progress of Arcturus Therapeutics Holdings Inc.’s (ARCT - Free Report) COVID-19 vaccine candidate on the fourth-quarter earnings call.
Arcturus’ earnings performance has been dismal over the trailing four quarters. The company’s earnings missed estimates in each of the last four quarters with the average negative surprise being 47.84%.
Shares of Arcturus have soared 399.1% so far this year against the industry‘s decrease of 14.9%.
In the last reported quarter, Arcturus delivered a negative earnings surprise of 95.74%.
Factors to Note
Arcturus has two clinical-stage candidates in its pipeline — a single dose, mRNA-based COVID-19 vaccine and a therapeutic candidate for ornithine transcarbamylase (OTC) deficiency.
The company’s COVID-19 vaccine candidate, ARCT-021, has shown favorable immunogenicity and safety profile when the company announced interim data from a phase I/II study in November last year. Based on this study data, the FDA and Singapore Health Sciences Authority granted permission to initiate a phase II study on the candidate.
The new phase II study will continue to evaluate both single-dose and prime-boost regimens of the candidate. Potential positive data from this study will support a phase III study, planned to begin in the second quarter. The company may provide an update on the progress of the phase II study on its fourth-quarter earnings call.
The company is developing OTC therapeutic candidate, ARCT-810, in two early-stage studies. Investors may ask questions on the future path for the candidate’s development on the earnings call.
During the quarter, the company planned to progress a new pipeline candidate, ARCT-032, to clinical-stage development for treating cystic fibrosis. Ongoing clinical studies and preparation for new clinical studies are likely to have driven operating expenses during the fourth quarter. However, the company may have recorded grant revenues, which are likely to have partially offset the increase in operating expense.
Meanwhile, the company records revenues from its strategic alliances and collaborations. However, revenues from these sources vary every quarter.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Arcturus this earnings season. The combination of a positive Earnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here.
Earnings ESP: Arcturus has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 92 cents per share.You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Arcturus carries a Zacks Rank #4 (Sell).
Arcturus Therapeutics Holdings Inc. Price and Consensus
Arcturus Therapeutics Holdings Inc. price-consensus-chart | Arcturus Therapeutics Holdings Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Moderna, Inc. (MRNA - Free Report) has an Earnings ESP of +0.57% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Clearside Biomedical, Inc. (CLSD - Free Report) has an Earnings ESP of +4.35% and a Zacks Rank #2.
Lexicon Pharmaceuticals, Inc. (LXRX - Free Report) has an Earnings ESP of +3.57% and a Zacks Rank #2.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>